Biomerica Statistics
Total Valuation
Biomerica has a market cap or net worth of $8.11 million. The enterprise value is $6.05 million.
Important Dates
The next estimated earnings date is Friday, October 10, 2025, after market close.
| Earnings Date | Oct 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biomerica has 2.82 million shares outstanding. The number of shares has increased by 9.22% in one year.
| Current Share Class | 2.82M |
| Shares Outstanding | 2.82M |
| Shares Change (YoY) | +9.22% |
| Shares Change (QoQ) | -7.98% |
| Owned by Insiders (%) | 5.74% |
| Owned by Institutions (%) | 2.47% |
| Float | 2.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.23 |
| Forward PS | n/a |
| PB Ratio | 1.76 |
| P/TBV Ratio | 2.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.80, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.80 |
| Quick Ratio | 1.80 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -92.99% and return on invested capital (ROIC) is -53.78%.
| Return on Equity (ROE) | -92.99% |
| Return on Assets (ROA) | -42.25% |
| Return on Invested Capital (ROIC) | -53.78% |
| Return on Capital Employed (ROCE) | -122.16% |
| Revenue Per Employee | $98,352 |
| Profits Per Employee | -$92,093 |
| Employee Count | 54 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 2.49 |
Taxes
In the past 12 months, Biomerica has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.92% in the last 52 weeks. The beta is 0.34, so Biomerica's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +14.92% |
| 50-Day Moving Average | 3.03 |
| 200-Day Moving Average | 3.78 |
| Relative Strength Index (RSI) | 47.69 |
| Average Volume (20 Days) | 32,289 |
Short Selling Information
The latest short interest is 219,391, so 7.79% of the outstanding shares have been sold short.
| Short Interest | 219,391 |
| Short Previous Month | 116,026 |
| Short % of Shares Out | 7.79% |
| Short % of Float | 8.27% |
| Short Ratio (days to cover) | 0.48 |
Income Statement
In the last 12 months, Biomerica had revenue of $5.31 million and -$4.97 million in losses. Loss per share was -$2.16.
| Revenue | 5.31M |
| Gross Profit | 498,000 |
| Operating Income | -5.14M |
| Pretax Income | -4.97M |
| Net Income | -4.97M |
| EBITDA | -5.05M |
| EBIT | -5.14M |
| Loss Per Share | -$2.16 |
Full Income StatementBalance Sheet
The company has $2.40 million in cash and $458,000 in debt, giving a net cash position of $1.94 million or $0.69 per share.
| Cash & Cash Equivalents | 2.40M |
| Total Debt | 458,000 |
| Net Cash | 1.94M |
| Net Cash Per Share | $0.69 |
| Equity (Book Value) | 4.11M |
| Book Value Per Share | 1.61 |
| Working Capital | 3.14M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.84M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.84M |
| FCF Per Share | -$1.36 |
Full Cash Flow StatementMargins
Gross margin is 9.38%, with operating and profit margins of -96.72% and -93.64%.
| Gross Margin | 9.38% |
| Operating Margin | -96.72% |
| Pretax Margin | -93.62% |
| Profit Margin | -93.64% |
| EBITDA Margin | -95.09% |
| EBIT Margin | -96.72% |
| FCF Margin | n/a |
Dividends & Yields
Biomerica does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.22% |
| Shareholder Yield | -9.22% |
| Earnings Yield | -62.20% |
| FCF Yield | -48.04% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 21, 2025. It was a reverse split with a ratio of 1:8.
| Last Split Date | Apr 21, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
Biomerica has an Altman Z-Score of -11.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.27 |
| Piotroski F-Score | 2 |
